
    
      This is a randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study
      designed to evaluate the efficacy, safety, and tolerability of treatment with SEP-4199
      monotherapy given as 200 mg/day or 400 mg/day compared with placebo for the treatment of
      major depressive episodes associated with bipolar I disorder (bipolar I depression).
    
  